R
Robert J. Crowder
Researcher at Washington University in St. Louis
Publications - 36
Citations - 5468
Robert J. Crowder is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Breast cancer & Estrogen receptor. The author has an hindex of 25, co-authored 36 publications receiving 5116 citations. Previous affiliations of Robert J. Crowder include University of Rochester.
Papers
More filters
Journal ArticleDOI
Genome remodelling in a basal-like breast cancer metastasis and xenograft
Li Ding,Matthew J. Ellis,Shunqiang Li,David E. Larson,Ken Chen,John W. Wallis,Chris Harris,Michael D. McLellan,Robert S. Fulton,Lucinda Fulton,Rachel Abbott,Jeremy Hoog,David J. Dooling,Daniel C. Koboldt,Heather K. Schmidt,Joelle Kalicki,Qunyuan Zhang,Lei Chen,Ling Lin,Michael C. Wendl,Joshua F. McMichael,Vincent Magrini,Lisa Cook,Sean McGrath,Tammi L. Vickery,Elizabeth L. Appelbaum,Katherine DeSchryver,Sherri R. Davies,Therese Guintoli,Li-li Lin,Robert J. Crowder,Yu Long Tao,Jacqueline E. Snider,Scott M. Smith,Adam F. Dukes,Gabriel E. Sanderson,Craig Pohl,Kim D. Delehaunty,Catrina Fronick,Kimberley A. Pape,Jerry S. Reed,Jody S. Robinson,Jennifer S. Hodges,William Schierding,Nathan D. Dees,Dong-Wei Shen,Devin P. Locke,Madeline E. Wiechert,James M. Eldred,Josh B. Peck,Benjamin J. Oberkfell,Justin T. Lolofie,Feiyu Du,Amy Hawkins,Michelle D O'Laughlin,Kelly E. Bernard,Mark L. Cunningham,Glendoria Elliott,Mark D. Mason,Dominic M. Thompson,Jennifer Ivanovich,Paul J. Goodfellow,Charles M. Perou,George M. Weinstock,Rebecca Aft,Mark A. Watson,Timothy J. Ley,Richard K. Wilson,Elaine R. Mardis +68 more
TL;DR: The differential mutation frequencies and structural variation patterns in metastasis and xenograft compared with the primary tumour indicate that secondary tumours may arise from a minority of cells within thePrimary tumour.
Journal ArticleDOI
Whole-genome analysis informs breast cancer response to aromatase inhibition
Matthew J. Ellis,Li Ding,Dong Shen,Jingqin Luo,Vera J. Suman,John W. Wallis,Brian A. Van Tine,Jeremy Hoog,Reece J. Goiffon,Theodore C. Goldstein,Sam Ng,Li Lin,Robert J. Crowder,Jacqueline E. Snider,Karla V. Ballman,Jason D. Weber,Ken Chen,Daniel C. Koboldt,Cyriac Kandoth,William Schierding,Joshua F. McMichael,Christopher A. Miller,Charles Lu,Chris Harris,Michael D. McLellan,Michael C. Wendl,Katherine DeSchryver,D. Craig Allred,Laura J. Esserman,Gary Unzeitig,Julie A. Margenthaler,Gildy Babiera,P. Kelly Marcom,J. M. Guenther,Marilyn Leitch,Kelly K. Hunt,John A. Olson,Yu Tao,Christopher G. Maher,Lucinda Fulton,Robert S. Fulton,Michelle Harrison,Ben Oberkfell,Feiyu Du,Ryan Demeter,Tammi L. Vickery,Adnan Elhammali,Helen Piwnica-Worms,Helen Piwnica-Worms,Sandra McDonald,Mark A. Watson,David J. Dooling,David M. Ota,Li-Wei Chang,Ron Bose,Timothy J. Ley,David Piwnica-Worms,Joshua M. Stuart,Richard K. Wilson,Elaine R. Mardis +59 more
TL;DR: To correlate the variable clinical features of oestrogen-receptor-positive breast cancer with somatic alterations, pretreatment tumour biopsies accrued from patients in two studies of neoadjuvant aromatase inhibitor therapy are studied by massively parallel sequencing and analysis.
Journal ArticleDOI
Phosphatidylinositol 3-Kinase and Akt Protein Kinase Are Necessary and Sufficient for the Survival of Nerve Growth Factor-Dependent Sympathetic Neurons
TL;DR: It is demonstrated that PI 3-kinase and Akt are both necessary and sufficient for the survival of NGF-dependent sympathetic neurons.
Journal ArticleDOI
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.
Shunqiang Li,Dong Shen,Jieya Shao,Robert J. Crowder,Wenbin Liu,Aleix Prat,Xiaping He,Shuying Liu,Jeremy Hoog,Charles Lu,Li Ding,Obi L. Griffith,Christopher A. Miller,Dave Larson,Robert S. Fulton,Michelle Harrison,Thomas B. Mooney,Joshua F. McMichael,Jingqin Luo,Yu Tao,Rodrigo Franco Gonçalves,Christopher E. Schlosberg,Jeffrey F. Hiken,Laila Saied,César Sánchez,Therese Giuntoli,Caroline Bumb,Crystal Cooper,R.T. Kitchens,Austin Lin,Chanpheng Phommaly,Sherri R. Davies,Jin Zhang,Megha Shyam Kavuri,Donna McEachern,Yiyu Dong,Cynthia X. Ma,Timothy J. Pluard,Michael Naughton,Ron Bose,Rama Suresh,Reida G. McDowell,Loren S. Michel,Rebecca Aft,William E. Gillanders,Katherine DeSchryver,Richard K. Wilson,Shaomeng Wang,Gordon B. Mills,Ana M. Gonzalez-Angulo,John R. Edwards,Christopher G. Maher,Charles M. Perou,Elaine R. Mardis,Matthew J. Ellis +54 more
TL;DR: Deep sequenced PDX models are an important resource for the search for genome-forward treatment options and capture endocrine-drug-resistance etiologies that are not observed in standard cell lines.
Journal ArticleDOI
Lower-Dose vs High-Dose Oral Estradiol Therapy of Hormone Receptor-Positive, Aromatase Inhibitor-Resistant Advanced Breast Cancer: A Phase 2 Randomized Study
Matthew J. Ellis,Feng Gao,Farrokh Dehdashti,Donna B. Jeffe,P. Kelly Marcom,Lisa A. Carey,Maura N. Dickler,Paula Silverman,Gini F. Fleming,Aruna Kommareddy,Shohreh Jamalabadi-Majidi,Robert J. Crowder,Barry A. Siegel +12 more
TL;DR: In women with advanced breast cancer and acquired resistance to aromatase inhibitors, a daily dose of 6 mg of estradiol provided a similar clinical benefit rate as 30 mg, with fewer serious adverse events.